Nuvation Bio Inc [NUVB] stock prices are down -1.01% to $2.95 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NUVB shares have gain 8.86% over the last week, with a monthly amount glided 19.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nuvation Bio Inc [NYSE: NUVB] stock has seen the most recent analyst activity on April 23, 2025, when Citizens JMP initiated its Mkt Outperform rating and assigned the stock a price target of $6. Previously, Jefferies upgraded its rating to Buy on March 27, 2024, and elevated its price target to $10. On March 26, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $5 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $2 on January 06, 2023. BTIG Research downgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to Market Perform for this stock on August 02, 2022, and downed its price target to $2.50. In a note dated May 04, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $14 on this stock.
The stock price of Nuvation Bio Inc [NUVB] has been fluctuating between $1.54 and $3.45 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Nuvation Bio Inc [NYSE: NUVB] shares were valued at $2.95 at the most recent close of the market. An investor can expect a potential return of 103.39% based on the average NUVB price forecast.
Analyzing the NUVB fundamentals
The Nuvation Bio Inc [NYSE:NUVB] reported sales of 14.36M for trailing twelve months, representing a surge of 236.79%. Gross Profit Margin for this corporation currently stands at 0.28% with Operating Profit Margin at -15.65%, Pretax Profit Margin comes in at -14.13%, and Net Profit Margin reading is -14.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.46 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.55.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.88 points at the first support level, and at 2.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.03, and for the 2nd resistance point, it is at 3.12.
Ratios To Look Out For
It’s worth pointing out that Nuvation Bio Inc [NYSE:NUVB]’s Current Ratio is 9.39. Further, the Quick Ratio stands at 9.38, while the Cash Ratio is 3.74. Considering the valuation of this stock, the price to sales ratio is 70.52, the price to book ratio is 2.67.
Transactions by insiders
Recent insider trading involved Markel Stacy, CHIEF PEOPLE OFFICER, that happened on Jun 18 ’25 when 10000.0 shares were purchased. Chief Financial Officer, Sauvage Philippe completed a deal on Jun 17 ’25 to buy 4000.0 shares. Meanwhile, Chief Financial Officer Sauvage Philippe bought 3300.0 shares on Jun 16 ’25.
